A novel approach to improve cardiac performance: Cardiac myosin activators

Heart Failure Reviews

Volumn 14, Issue 4, 2009, Pages 289-298

  Teerlink, John R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiac function; Cardiac myosin activator; CK 1827452; Heart failure; Inotrope; Systolic ejection time

Indexed keywords

ACTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CK 0689705; CK 1122534; CK 1213296; CK 1827452; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; INOTROPIC AGENT; ISOPRENALINE; MYOSIN; MYOSIN ACTIVATOR; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROPRANOLOL; TROPONIN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

CALCIUM HOMEOSTASIS; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FIRST PASS EFFECT; HEART CONTRACTION; HEART DEPOLARIZATION; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE DP-DT; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART PERFORMANCE; HEART STROKE VOLUME; HEART VENTRICLE EJECTION TIME; HUMAN; INOTROPISM; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NONHUMAN; REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARDIAC MYOSINS; CARDIOTONIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; UREA; VENTRICULAR FUNCTION, LEFT;

EID: 70449112931     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-009-9135-0     Document Type: Review

References (29)

1. W Rosamond K Flegal K Furie A Go K Greenlund N Haase SM Hailpern M Ho V Howard B Kissela S Kittner D Lloyd-Jones M McDermott J Meigs C Moy G Nichol C O'Donnell V Roger P Sorlie J Steinberger T Thom M Wilson Y Hong 2008 For the American heart association statistics committee and stroke statistics s. heart disease and stroke statistics-2008 Update: a report from the American heart association statistics Committee and stroke statistics subcommittee Circulation 117 e25 e146 10.1161/CIRCULATIONAHA.107.187998 10.1161/CIRCULATIONAHA.107.187998 18086926
2. GC Fonarow WG Stough WT Abraham NM Albert M Gheorghiade BH Greenberg CM O'Connor JL Sun CW Yancy JB Young 2007 Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry J Am Coll Cardiol 50 768 777 10.1016/j.jacc.2007.04.064 10.1016/j.jacc.2007.04.064 17707182 (Pubitemid 47243795)
3. JW Petersen GM Felker 2008 Inotropes in the management of acute heart failure Crit Care Med 36 S106 S111 10.1097/01.CCM.0000296273.72952.39 1:CAS:528:DC%2BD2sXhsVOisbbO 18158469
4. AC Hinken RJ Solaro 2007 A dominant role of cardiac molecular motors in the intrinsic regulation of ventricular ejection and relaxation Physiology (Bethesda, MD) 22 73 80 10.1152/physiol.00043.2006 1:CAS:528: DC%2BD2sXlsF2nsLc%3D
5. RJ Solaro PP de Tombe 2008 Review focus series: sarcomeric proteins as key elements in integrated control of cardiac function Cardiovasc Res 77 616 618 10.1093/cvr/cvn004 10.1093/cvr/cvn004 1:CAS:528:DC%2BD1cXjvVaju7s%3D 18192242 (Pubitemid 351301879)
6. JA Spudich 1994 How molecular motors work Nature 372 515 518 10.1038/372515a0 10.1038/372515a0 1:CAS:528:DyaK2MXisFKkt7s%3D 7990922 (Pubitemid 24368526)
7. RD Vale RA Milligan 2000 The way things move: looking under the hood of molecular motor proteins Science 288 88 95 10.1126/science.288.5463.88 10.1126/science.288.5463.88 1:CAS:528:DC%2BD3cXisVGjsrw%3D 10753125 (Pubitemid 30203035)
8. JN Cohn SO Goldstein BH Greenberg BH Lorell RC Bourge BE Jaski SO Gottlieb F McGrew 3rd DL DeMets BG White 1998 A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone trial investigators N Engl J Med 339 1810 1816 10.1056/NEJM199812173392503 10.1056/NEJM199812173392503 1:CAS:528:DyaK1MXisFChuw%3D%3D 9854116 (Pubitemid 29005785)
9. MS Cuffe RM Califf KF Adams Jr R Benza R Bourge WS Colucci BM Massie CM O'Connor I Pina R Quigg MA Silver M Gheorghiade 2002 Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial J Am Med Assoc 287 1541 1547 10.1001/jama.287.12.1541 10.1001/jama.287.12.1541 1:CAS:528:DC%2BD38XisVegt78%3D (Pubitemid 34269999)
10. GM Felker RL Benza AB Chandler JD Leimberger MS Cuffe RM Califf M Gheorghiade CM O'Connor 2003 Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study J Am Coll Cardiol 41 997 1003 10.1016/S0735-1097(02)02968-6 10.1016/S0735-1097(02)02968-6 1:CAS:528:DC%2BD3sXislejsLk%3D 12651048 (Pubitemid 36315544)
11. M Packer JR Carver RJ Rodeheffer RJ Ivanhoe R DiBianco SM Zeldis GH Hendrix WJ Bommer U Elkayam ML Kukin, et al. 1991 Effect of oral milrinone on mortality in severe chronic heart failure. The promise study research group N Engl J Med 325 1468 1475 1:STN:280:DyaK38%2FkvFGlsQ%3D%3D 1944425
12. Cytokinetics Inc. www.cytokinetics.com. Accessed 20 Oct 2008
13. Niu C, Cox DR, Lee KH, Sylvester S, Sueoka SH, Qian X, Feng B, Malik F, Morgans D, Hartman JJ, Sakowicz R, Elias KA (2004) Cellular responses of the myosin activator CK689705 in normal and heart failure. Mol Biol Cell 15:271A
14. Rodriguez HM, Sylvester S, Qian X, Morgan BP, Morgans DJ, Malik F, Sakowicz R (2004) Activation of cardiac sarcomere ATPase by CK1122534, a small molecule agent that specifically targets cardiac myosin. Mol Biol Cell 15:32A
15. AF Straight A Cheung J Limouze I Chen NJ Westwood JR Sellers TJ Mitchison 2003 Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor Science 299 1743 1747 10.1126/science.1081412 10.1126/science.1081412 1:CAS:528:DC%2BD3sXitVSjt7c%3D 12637748 (Pubitemid 36337202)
16. CR Niu RL Anderson DR Cox BP Morgan DJ Morgans F Malik KA Elias 2004 The cardiac myosin activator, CK1122534, increases contractility in adult cardiac myocytes but does not affect the calcium transient or depend on second messenger Circulation 110 478 479
17. Malik F, Shen YT, Katori T, Sueoka SH, Anderson R, Cox D, Garard M, Hartman J, Kim SJ, Kraynack E, Kuklov A, Lee KH, Lu PP, Muci A, Niu C, Rodriguez H, Suehiro I, Sylvester S, Tochimoto T, Elias KA, Morgan BP, Sakowicz R, Kass DA, Vatner SF, Morgans DJ (2005) Direct activation of cardiac myosin, a novel mechanism for improving cardiac function. Circ Res 97:E34
18. Anderson RL, Sueoka SH, Rodriguez HM, Lee KH, Cox DR, Kawas R, Morgan BP, Sakowicz R, Morgans DJ, Malik F, Elias KA (2005) In vitro and in vivo efficacy of the cardiac myosin activator CK-1827452. Mol Bio Cell 16 (Abstract #1728)
19. Rodriguez HM, Kawas R, Hartman JJ, Malik F, Sakowicz R (2007) The cardiac myosin activator, CK-1827452, accelerates the enzymatic step gating entry of myosin into its force generating state. Biophysical society meeting abstracts. Biophys J 2007:481A
20. RL Anderson M Pokrovskii KA Elias 2007 Effects of cardiac myosin activators on excitation-contraction (E-C) coupling in venricular myocytes. Biophysical society meeting abstracts Biophys J 2007 133a
21. RL Anderson SH Sueoka KH Lee HM Rodriguez RF Kawas G Godinez BP Morgan R Sakowicz DJ Morgans F Malik KA Elias 2006 In vitro and in vivo characterization of CK-1827452, a selective cardiac myosin activator J Card Fail 12 S86 10.1016/j.cardfail.2006.06.292 10.1016/j.cardfail.2006.06.292
22. YT Shen Y Zhang DJ Morgans SF Vatner F Malik 2008 A novel inotropic agent that activates cardiac myosin and increases cardiac contractility without increasing MVO2 in heart failure with left ventricular hypertrophy J Am Coll Card 51 10, Suppl 1 A54 10.1016/j.jacc.2008.02.004
23. JR Teerlink FI Malik CP Clarke KG Saikali RD Escandon JH Lee AA Wolff 2006 The selective cardiac myosin activator, CK-1827452, increases left ventricular systolic function by increasing ejection time: results of a first-in-human study of a unique and novel mechanism J Card Fail 12 763 10.1016/j.cardfail.2006.10.007 10.1016/j.cardfail.2006.10.007
24. FI Malik KG Saikali CP Clarke JR Teerlink AA Wolff 2007 Systolic ejection time is a sensitive indicator of left ventricular systolic function during treatment with the selective cardiac myosin activator, CK-1827452 J Card Fail 13 6, Suppl 2 S145 S146 10.1016/j.cardfail.2007.06.614 10.1016/j.cardfail.2007.06. 614
25. F Malik JR Teerlink RD Escandon CP Clarke AA Wolff 2006 The selective cardiac myosin activator, CK-1827452, a calcium-independent inotrope, increases left ventricular systolic function by increasing ejection time rather than the velocity of contraction Circulation 114 II 441
26. JGF Cleland EM Nifontov JJV McMurray R Senior CC Lang CP Clarke D Francis BH Greenberg J Mayet M Monaghan L Neyses VA Tsyrlin JH Goldman JR Teerlink G Brand JH Lee KG Saikali AA Wolff FI Malik 2008 First clinical trial of the selective cardiac myosin activator, CK-1827452, in heart failure: effect of dose and plasma concentration on systolic function Eur J Heart Fail Suppl 7 189 190 10.1016/S1567-4215(08)60526-3 10.1016/S1567-4215(08)60526-3
27. JGF Cleland FI Malik 2008 The selective cardiac myosin activator, CK-1827452, increases systolic function in heart failure J Card Fail 14 S67 10.1016/j.cardfail.2008.10.012 10.1016/j.cardfail.2008.06.178
28. M Jerling T Chew RD Escandon JH Lee KG Saikali E Venables CP Clarke F Malik AA Wolff 2007 Oral bioavailability of the selective cardiac myosin activator, CK-1827452: chronic oral inotropic therapy for heart failure? J Card Fail 13 6, Suppl 2 S148 10.1016/j.cardfail.2007.06.622 10.1016/j.cardfail.2007. 06.622
29. JD Parker AD Michaels DA Kass AA Wolff GM Felker FI Malik 2008 Rationale and design for a phase II study evaluating the effect of the cardiac myosin activator, CK-1827452, on cardiac function, hemodynamics, and myocardial oxygen consumption in patients with heart failure J Card Fail 14 S79 10.1016/j.cardfail.2008.06.438 10.1016/j.cardfail.2008.06.438